Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic
Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic
复制标题
DOI：
10.5152/eurjrheum.2020.2067
复制
发表时间：
2020-08-01
影响因子：
1.9
通讯作者：
Geetha, Duvuru
中科院分区：
文献类型：
--
作者：
Gapud, Eric J.;Kronbichler, Andreas;Geetha, Duvuru
自2019年12月在中国首次描述严重急性呼吸综合征冠状病毒2型（SARSCoV-2）感染以来，它已演变为一场大流行病，并成为一场前所未有的全球性危机，压倒了全球的医疗保健系统。迄今为止对现有文献的分析表明，除年龄较大外，患有基础合并症（包括高血压、糖尿病、心脏病）的患者发生重度疾病的风险更高，死亡率也更高。世界各地的从业者也越来越担心，免疫抑制患者（包括自身免疫性疾病患者）可能会增加患2019冠状病毒病（COVID-19）并伴有严重并发症的风险。关于抗中性粒细胞胞浆抗体（ANCA）相关性血管炎如何改变COVID-19的易感性、临床表现和病程，我们知之甚少。在这篇综述中，我们讨论了当前ANCA相关血管炎治疗设备的作用机制和挑战，并概述了COVID-19大流行期间ANCA相关血管炎的管理方法。
Since the first description of infections with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) in China in December 2019, it has evolved into a pandemic and emerged as an unprecedented worldwide crisis overwhelming healthcare systems globally. Analysis of the available literature to date suggests that, in addition to older age, patients with underlying co-morbidities including hypertension, diabetes, heart disease are at higher risk for severe disease with increased mortality. Practitioners around the world also have become increasingly concerned that immunosuppressed patients including those with autoimmune diseases may be at increased risk for developing Coronavirus Disease 2019 (COVID-19) with serious complications. Very little is known about how anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis modifies the susceptibility, clinical presentation and disease course of COVID-19. In this review, we discuss the mechanism of action and challenges of the current therapeutic armamentarium of ANCA-associated vasculitis and outline approaches to management of ANCA-associated vasculitis during the COVID-19 pandemic.